Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US

Journal of Medical Economics

Volumn 18, Issue 11, 2015, Pages 930-943

  Saint Laurent Thibault, Catherine ^a   Özer Stillman, Ipek ^b   Chen, Stephanie ^c   Getsios, Denis ^b   Proskorovsky, Irina ^a   Hernandez, Luis ^b   Dixit, Shailja ^d  

^a Modeling and Simulation   (Canada)

^b EVIDERA   (United States)

^c ASTRAZENECA   (United Kingdom)

^d FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Cost; Cost benefit analysis; Dementia; Effectiveness; Memantine

Indexed keywords

FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; CHOLINESTERASE INHIBITOR; DELAYED RELEASE FORMULATION; MEMANTINE; NEUROLEPTIC AGENT;

ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEALTH STATUS; HUMAN; MALE; MORTALITY; MULTIPLE SCLEROSIS; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); UNITED KINGDOM; AGED; ALZHEIMER DISEASE; CAREGIVER; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DELAYED RELEASE FORMULATION; ECONOMICS; MARKOV CHAIN; PHASE 3 CLINICAL TRIAL; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CAREGIVERS; CHOLINESTERASE INHIBITORS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MARKOV CHAINS; MEMANTINE; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84945449791     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1063501     Document Type: Article

References (34)

1. Alzheimer's Association. 2014 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia 2014; 10. Available at: https://www.alz.org/downloads/Facts-Figures-2014.pdf
2. Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80:1778-83
3. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 2010;22:346-72
4. Karttunen K, Karppi P, Hiltunen A, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. Int J Geriatr Psychiatry 2011;26:473-82
5. California Workgroup on Guidelines for Alzheimer's Disease Management, State of California, Department of Public Health. Guideline for Alzheimer's Disease Management. Final report, 2008. Available at: http://www.alz.org/socal/images/professional-GuidelineFullReport.pdf
6. Alzheimer's Disease Program, Chronic Disease Branch Division for Disease Control and Prevention Services, Texas Department of State Health Services. Clinical best practices for early detection, diagnosis, and pharmaceutical and non-pharmaceutical treatment of persons with Alzheimer's Disease. Publication No 44-14023. February 2013. Available at: http://dshs.state.tx. us/alzheimers/pdf/Early-Detection-Final.doc
7. Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement 2013;9:326-331
8. Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67:57-63
9. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open 2012;2:e000917
10. Green C. Modelling disease progression in Alzheimer's disease. A review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics 2007;25:735-50
11. Pouryamout L, Dams J, Wasem J, et al. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of costeffectiveness analyses. Drugs 2012;72:789-802
12. Touchon J, Lachaine J, Beauchemin C, et al. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ 2014;15:791-800
13. Lachaine J, Beauchemin C, Legault M, et al. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can J Psychiatry 2011;56:596-604
14. Pfeil AM, Kressig RW, Szucs TD. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland. Swiss Med Wkly 2012;142:w13676
15. Weycker D, Taneja C, Edelsberg J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin 2007;23:1187-97
16. Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 2013;27:469-78
17. Hartz S, Getsios D, Tao S, et al. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation. BMC eurology 2012;12
18. Getsios D, Blume S, Ishak KJ, et al. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation. Pharmacoeconomics 2010;28:411-27
19. Bergh S, Selbaek G, Engedal K. Reliability and validity of the Norwegian version of the Severe Impairment Battery (SIB). Int J Geriatr Psychiatry 2008;23:896-902
20. Tun SM, Murman DL, Long HL, et al. Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry 2007;15:314-27
21. Arias E. United States life tables, 2008. National vital statistics reports; vol 61 no 3. Hyattsville, MD: National Center for Health Statistics, 2012. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61-03.pdf
22. Fitzpatrick AL, Kuller LH, Lopez OL, et al. Survival following dementia onset: Alzheimer's disease and vascular dementia. J Neurol Sci 2005;229-230:43-9
23. Lachaine J, Beauchemin C, Crochard A, et al. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Regie de l'Assurance Maladie du Quebec database. Can J Psychiatry 2013;58:195-200
24. Red Book Online. Truven Health Analytics. Available at: www.redbook.com Accessed on: August 27, 2013
25. SDI Vector One Payer, Total prescription utilization for the Alzheimer's class of the last four calendar quarters ending June 2013. Available at: http://www.imshealth.com
26. Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008;179:438-46
27. Gustavsson A, Brinck P, Bergvall N, et al. Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients. Alzheimers Dement 2011;7:318-27
28. Hauber AB, Gnanasakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Pharmacoeconomics 2000;17:351-60
29. Bell CM, Araki SS, Neumann PJ. The association between caregiver burden and caregiver health-related quality of life in Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:129-36
30. Bureau of Labor Statistics. Consumer Price Index, 2013, Area: US city average, Item: medical care, Base period: 1982-84, Years: 1995-2013. Available at: http://www.bls.gov/cpi/. Accessed on June 3, 2013
31. Leon J, Neumann PJ, Hermann RC, et al. Health-related quality-of-life and service utilization in Alzheimer's disease: a cross-sectional study. Am J Alzheimer's Dis Other Demen 2000;15:94-108
32. Weinstein MC, Siegel JE, Gold MR, et al. REcommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8
33. Alzheimer's Association. 2013 Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia 2013;9. Available at: https://www.alz.org/downloads/facts-figures-2013.pdf
34. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-33